Science. People. Affordable and innovative medicines. Synthon is a company committed to delivering quality medicines at sustainable pricing through innovative science 2 www.synthon.com Science. People. Affordable and innovative medicines. across everytechnologicalplatform. production andtodeliveryofourproducts toourcustomers– everything wedo–from thediscoveryphaseinR&Dthrough highest standards ofscientific andoperationalexcellencein remedies. To makethishappen,weholdourselvestothe treatments more affordable andincrease accesstoimportant provision ofhigh-quality genericmedicineswemake therapeutic areas withhigh unmetmedicalneed.Through the we willprovide treatment optionsforpatientsinselected and well-being.Withourportfolioofinnovativemedicines, the needsofpeopleworldwideandhelpimprove theirhealth of ourcompany. We worktodeveloptherapiesthataddress Innovation andcontinuousimprovement are theheartbeat challenges oftodayandtomorrow. people intoactiontoprovide solutionstothehealthcare put ourcutting-edgescience,abilitytoinnovateandtalented access toqualitymedicinesatsustainablepricing.We will We believethateveryoneontheplanetisentitledtohave Good healthissomethingwealldesire anddeserve. innovation Science-driven

4 www.synthon.com Science. People. Affordable and innovative medicines. the peoplemostin need ofthem. strengths inenablingustodeliverhigh-qualitymedicines products. Thisis,andhasalwaysbeen,oneofourgreat ingredients through tomanufacture andsaleofourdrug development andproduction ofactivepharmaceutical facet ofthedevelopmentchainbeginning withresearch, of averticallyintegratedorganization. Today, wecontrol every Synthon’s strategyfrom itsinceptionincludedthedevelopment looking tofindpartnersforourproducts inallmajormarkets. We continuetoinvestandexpandglobally andare continually to deliveronourambitions. our worldwideinfrastructure isfullyriggedup,positioningus and earlylaunches–inourmaincampustheNetherlands, antibody-drug conjugates(ADCs)–uptoPhaseIIIclinicaltrials monoclonal antibodies(mAbs)andtheproduction of laboratories andGMPfacilitiesforthemanufacture of local markets.Withourstate-of-the-artbiopharmaceutical andChilemanufacture andpackageproducts forthe , ChileandSpain.Furthermore, ourfacilitiesin product manufacturingfacilitiesintheCzechRepublic, around 100countries.We haveglobally-orientedAPIordrug Our products are currently approved byregulatory agenciesin operationglobal growing, A

6 www.synthon.com Science. People. Affordable and innovative medicines. Our strategy Our pharmaceuticals. position uswellforourfuture inspecialty distribute high-qualitypharmaceuticals R&D andproven abilitytomanufacture and technological platforms.Ourinnovative biological andnewchemicalentity We haveextendedthismodeltoournew manufacturing andsupplychainoperations. regulatory andIPexpertise,world-class to improve ourR&Dcapabilities,global is expandingaswecontinuouslystrive developed forsmall-moleculegenerics The vertically-integratedmodelwe leader inspecialtypharmaceuticals. Synthon aimstobecomearecognized

8 www.synthon.com Science. People. Affordable and innovative medicines. capabilities R&D Growing to andincludingPhaseIII. phase compoundsintoclinical trials-up well-equipped totakeourdevelopment clinical drugdevelopmentunitwhichis worldwide. We haveourownfully-functional we carryoutanalyticalandclinicalresearch to chemicaland(bio)pharmaceuticalR&D, in basicandappliedresearch. Inaddition to ourcompany. We therefore investheavily the overallvaluechainandare essential Research anddevelopmentremain vitalto

10 www.synthon.com Science. People. Affordable and innovative medicines. generics Distinctive in example, Synthonistheonlycompanyto guarantee alongproduct lifespan.Asan needs, supportedbystrong patentsthat in first-ratemedicinesthatmeetmarket and sophisticateddosageforms.Thisresults with aclearpreference forcomplexsynthesis that isthepursuitofinnovativeexcellence One commonfactordrivesourbusinessand treat alarge numberofdiverseindications. many therapeuticareas withmedicinesto portfolio. Ourgenericproduct rangecovers hybrids formthebackboneofourproduct Complex small-moleculegenericsand regulatory applications. rich withresearch projects andpending prices. Furthermore, ourgenericpipelineis possible opportunityandsoldatcompetitive Our products are marketedattheearliest relapsing remitting multiplesclerosis. forpatientswithand safealternative thereby providing anaffordable, efficacious version oftheoriginatormedicineCopaxone glatiramer acetate,atherapeuticallyequivalent Europe forbothdosagestrengths of have obtainedregulatory clearancein ® , 12 www.synthon.com Science. People. Affordable and innovative medicines. biopharmaceutical pipeline biopharmaceutical Promising diagnostics andtoxicology. protein interaction,companion pharmacology, team ofprofessionals, experts in programs isconductedby ourwell-equipped pre-clinical R&Dworkfor our innovative of novelmedicines.Theextensive analytics, formulationanddevelopment including (site-specific)conjugation, purification andprotein modification recombinant protein production, protein chemistry, celllinedevelopment,and small-molecule chemistries,medicinal diverse technologies,includingcomplex business coversawidespectrumofvery development. Thishighlyinnovative focuses onnewmolecularentity proteins) in2007.Nowadays,thefranchise ceutical medicinesbasedontherapeutic franchise (thedevelopmentofbiopharma Synthon starteditsbiopharmaceutical

in vivo pharmacology,

in vitro

- oncology andautoimmunediseases. with ahighunmetmedicalneed,notablyin complex andseriousconditionstopatients bring medicinesfortreating medically and reflects ourfocusandcommitmentto clinical-stage programs inthecomingyears well-positioned toencompassmultiple Our pipelineofnewmolecularentitiesis platform togeneratenovelADCcandidates. technology, includingauniquelinker-drug as wellantibody-drugconjugate(ADC) monoclonal antibody(mAb)technology, Our principaltechnologiesinclude

14 www.synthon.com Science. People. Affordable and innovative medicines. 16 www.synthon.com Science. People. Affordable and innovative medicines. appropriate stageorvalueinflectionpoint. technology orpipelineproject atthe market, or, alternatively, partneringa taking agivenproduct allthewayto partner eachprogram. Thismightinvolve: Synthon willchoosetheoptimumtimingto In termsofcommercializing itsprograms, over 200partnercompaniestoday. success ofourefforts thatwenowhave products tomarket.Suchhasbeenthe cycle timesandbringmuch-needed costs, delivershortproduct development partner companies.Thishelpstomanage with anddrawuponthespecialistskillsof partnerships enablesustoshare knowledge developing robust business-to-business marketing partners.Ourstrategyof scientists, research institutionsand upon strong partnershipswithleading We believeinacollaborativemodelbased collaborative partnerships through Strength

18 www.synthon.com Science. People. Affordable and innovative medicines. property Intellectual operation ismaintained. and aseamlesseffective business ensure thatourinterests are fullyprotected expertise athand,wecanproactively and supportstaff. Byhavingtherightlegal informationspecialistspatent attorneys, legal representation andemployin-house To thisend,wehaveaccesstohigh-quality regard topatentandregulatory issues. our interests worldwide,particularlywith industry. We activelypromote anddefend crucial factorinthepharmaceutical Intellectual property rightswillremain a

20 www.synthon.com Science. People. Affordable and innovative medicines. Affairs Regulatory build adossierforsubmission. support thatcaneventuallybeusedto count ondetaileddocumentationand submission, butourcounterpartscan our biopharmaceuticalsbefore regulatory FDA andTGA.Generally, weout-license of regulatory authorities, such astheEMA, pharmaceutical andclinicalrequirements registration files,compliant withthechemical, more than100countries. We compile and ever-changing regulatory regimes in smallest detail–withincreasingly stringent our expertsare familiar– downtothe world. Inpracticalterms,thismeansthat trouble-free registration, wherever inthe including allcomponentsnecessaryfor customers withacompleteproduct, In ourGenericsbusiness,weprovide our

22 www.synthon.com Science. People. Affordable and innovative medicines. from asmallNijmegen-basedcompany growth.international Synthonquicklygrew product markedthestartofourrapid cardiogenic shock.Thesuccessofthisfirst used inthetreatment ofheartfailure and dobutamine, asympathomimeticdrug the developmentofagenericversion making healthcare more affordable ledto years, ourcreative visionandpassionfor Synthon wasfoundedin1991.Withintwo by example Leadership level ofmanagement. and entrepreneurial capabilityatevery technical expertise,businessdiscipline possible withouttherightcombinationof the world.Thiswouldnothavebeen production plantsinninecountriesaround people, andlaboratories,offices and headcount ofover1,900highlyeducated the fully-fledgedcompanyitistodaywith a employing fewerthanahundred peopleinto

24 www.synthon.com Science. People. Affordable and innovative medicines. talented people A core of women whoshare thesame valuesand attract andreward talentedmenand quality ofourpeople.We openlyseekto Our continuedsuccessdependsonthe focal point:thepatient. new molecularentities–toourultimate whether theyare complexgenericsor important medicines–irrespective of all share ourcommitmenttobringing products, whoare teamplayers,butabove hard toproduce commercially viable disciplines, whoare prepared towork are willingtoshare knowledgewithother expertise. Inshort,werequire peoplewho picture andthinkoutside their ownfieldof colleagues tobeableseethebigger also howyouachieveit.We wantour success isnotjustwhatyouachieve,but satisfaction intheirwork.We believethat for Synthondosowithprideandreal core beliefsisthatthepeople whowork new andeffective medicines. Oneofour the drivetocontributecreation of ambitious goals.Theseare individualswith team forthegoodofourcompanyand and abletoworkselflesslyaspartof a who are bothentrepreneurial inattitude

26 www.synthon.com Science. People. Affordable and innovative medicines. Synthon MexicoS.A.deC.V. Guadalajara, Mexico Synthon Pharmaceuticals,Inc. Durham, NC,UnitedStates Synthon ChileLtda. Santiago, Synthon Argentina S.A. San Lorenzo, Argentina Synthon Headquarters Nijmegen, theNetherlands Synthon HispaniaS.L. Barcelona, Synthon s.r.o. Blansko, CzechRepublic Synthon LLC Moscow, Russia Global Presence Global Synthon Korea Co.Ltd. Seoul, SouthKorea 28 www.synthon.com Science. People. Affordable and innovative medicines. www.synthon.com © SynthonHoldingBV September 2018 Maastricht, TheNetherlands Drukkerij Walters Printing Maastricht, TheNetherlands Zuiderlicht Design Nijmegen, TheNetherlands Corporate Communications Synthon HoldingBV Editorial coordination and clickonCareers. opportunities, pleasevisitwww.synthon.com If youwouldliketoknowmore about job (+31) 243727700 [email protected] Business DevelopmentBiopharmaceuticals (+31) 243727700 [email protected] Business DevelopmentGenerics please feelfree tocontactus. If youare interested inourproduct portfolio, Please visitwww.synthon.com Would more youliketolearn aboutSynthon? Contact

in thisbrochure. the reliance onanyinformationcontained liable foranyconsequencesasaresult of cannot berelied upon.Synthonisnot inconsistencies andforthatreason it possible care. Itmayhowevercontain It hasbeencomposedwiththegreatest composed forhealthcare professionals. pharmaceutical products andhasbeen This brochure containsinformationon appreciated. However, credit toSynthonwouldbe content inotherpublicationsispermitted. All rightsreserved. Reproduction ofthe Copyright ©2018SynthonHoldingBV. Disclaime r